IP Library Granted Patent US 6,843,998
Granted Patent B1
US 6,843,998 · App. 09/548,409 · Granted Jan 18, 2005

Methods and compositions for the treatment of pancreatitis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,843,998
App. No.
09/548,409
Granted
Jan 18, 2005
Kind
B1
Abstract

Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

Claims (10)

1. A composition for the treatment of acute pancreatitis in a mammal comprising, a first element comprising a binding element able to specifically bind a pancreatic acinar cell CCK receptor under physiological conditions, a second element comprising a translocation element derived from a clostridial neurotoxin heavy chain able to facilitate the transfer of a polypeptide across a vesicular membrane, and a third element comprising a therapeutic element derived from a clostridial neurotoxin light chain able, when present in the cytoplasm of a pancreatic cell, to inhibit enzymatic secretion by said pancreatic cell.

2. The composition of claim 1 wherein said therapeutic element will cleave a SNARE protein, wherein cleavage of said SNARE protein inhibits said secretion.

3. The composition of claim 2 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

4. The composition of claim 2 wherein said CCK receptor is the human CCK A receptor.

5. The composition of claim 4 wherein the binding element of said therapeutic polypeptide comprises a human CCK A amino acid sequence modified by the presence of a C-terminal amidated phenylalanine and a sulfated tyrosine at the position 7 residues from the carboxyl terminus.

6. The composition of claim 5 wherein said CCK A amino acid sequence comprises SEQ ID NO: 6.

7. The composition of claim 6 wherein said CCK A amino acid sequence comprises SEQ ID NO: 5.

8. The composition of claim 6 wherein said CCK A amino acid sequence comprises SEQ ID NO: 4.

9. The composition of claim 6 wherein said CCK A amino acid sequence comprises SEQ ID NO: 3.

10. The composition of claim 6 wherein said CCK A amino acid sequence comprises SEQ ID NO: 2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2003
From: ALLERGAN SALES, INC. (MERGED INTO ALLERGAN SALES, LLC 6/3/2002)
To: ALLERGAN, INC.
Reel/Frame 013898/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2000
From: STEWARD, LANCE E.; SACHS, GEORGE; AOKI, KEI ROGER
To: ALLERGAN SALES, INC.
Reel/Frame 010726/0276 →